2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Amino acid Transporter
  5. Amino acid Transporter Inhibitor

Amino acid Transporter Inhibitor

Amino acid Transporter Inhibitors (11):

Cat. No. Product Name Effect Purity
  • HY-120139
    KMH-233
    		Inhibitor 99.75%
    KMH-233, a potent, reversible and selective inhibitor of l-type amino acid transporter LAT1/SLC7A5, inhibits the uptake of LAT1 substrate, l-leucin (IC50=18 μM) as well as cell growth. KMH-233 significantly potentiates the efficacy of Bestatin and Cisplatin even at low concentrations (25 μM).
  • HY-B1274
    Cinromide
    		Inhibitor 99.83%
    Cinromide is an anticonvulsant agent. Cinromide inhibits epithelial neutral amino acid transporter B0AT1 (SLC6A19) with an IC50 of 0.5 μM.
  • HY-W402682
    SXC2023
    		Inhibitor 99.83%
    SXC2023 is an inhibitor for solute carrier family 7 member 11 (SLC7A11). SXC2023 exhibits antitumor efficacy, and ameliorates central nervous system disorder through downregulation of glutamate export.
  • HY-161137
    LQFM215
    		Inhibitor 99.91%
    LQFM215 is a proline transporter (PROT) inhibitor. LQFM215 inhibits proline transport by competitively binding to the active site of PROT. LQFM215 effectively reduces hyperlocomotion and enhances social interaction.
  • HY-176719
    AKR1B1/STAT3/SLC7A11-regulator-1
    		Inhibitor
    AKR1B1/STAT3/SLC7A11-regulator-1 (5a) is an AKR1B1/STAT3/SLC7A11 regulator that reverses DOX resistance in MCF-7/ADR cells by enhancing ferroptosis activity. AKR1B1/STAT3/SLC7A11-regulator-1 can be used in breast cancer research.
  • HY-162864
    JX237
    		Inhibitor 98.84%
    JX237 is an inhibitor of the epithelial neutral amino acid transporter B0AT1 (SLC6A19) with an IC50 value of 31 nM. SLC6A19 is the main transporter for the absorption of neutral amino acids in the intestines and their reabsorption in the kidneys. By inhibiting B0AT1, JX237 can be used for the study of disorders of amino acid metabolism.
  • HY-156682
    JNT-517
    		Inhibitor 99.00%
    JNT-517 is an orally active, selective SLC6A19 allosteric inhibitor with an IC50 of 47 nM for human SLC6A19. JNT-517 can be used for the study of phenylketonuria (PKU).
  • HY-153763
    PROT-IN-1
    		Inhibitor ≥98.0%
    PROT-IN-1 (Compound 2) is a proline transporter (PROT) inhibitor (IC50: 1.48 μM). PROT-IN-1 can be used for research of cognitive disorders.
  • HY-158161
    SLC6A19-IN-1
    		Inhibitor
    SLC6A19-IN-1 (Compound 16) is a SLC6A19 inhibitor. SLC6A19-IN-1 can be used to study diseases with abnormal amino acid levels, such as phenylketonuria (PKU).
  • HY-117251
    LP-403812
    		Inhibitor
    LP-403812 is a high affinity proline transporter (PROT) inhibitor that produces dose-dependent inhibition of hPROT (IC50=0.11 μM; Ki=0.12 μM) and also inhibits the activity of mouse brain synaptosomal mPROT with the same potency (IC50=0.23 μM). LP-403812 can be used to study the function of PROT in the brain.
  • HY-113745
    LX-6171
    		Inhibitor
    LX-6171 is an orally active SLC6A7 inhibitor. LX-6171 can be used to study diseases characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.